m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00244)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
EPHB2
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 1 (YTHDF1) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF1 | ||
Cell Line | AGS cell line | Homo sapiens |
Treatment: shYTHDF1 AGS
Control: shControl AGS
|
GSE159425 | |
Regulation |
|
logFC: -7.59E-01 p-value: 2.20E-04 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between EPHB2 and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 1.91E+00 | GSE63591 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contribute to regeneration. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Muscular dystrophies | ICD-11: 8C70 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | NB4 cell line | Homo sapiens |
Treatment: shFTO NB4 cells
Control: shNS NB4 cells
|
GSE103494 | |
Regulation |
|
logFC: 1.37E+00 p-value: 3.20E-04 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | FTO depended on its m6A RNA demethylase activity to activate PDGFRB/Ephrin type-B receptor 2 (ERK/EPHB2) signaling axis. FTO-mediated m6A demethylation plays an oncogenic role in NPM1-mutated Acute myeloid leukemia(AML). | |||
Target Regulation | Up regulation | |||
Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | OCI-AML-3 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1844 |
OCI-AML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1619 | |
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by HNRNPA2B1 | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Treatment: HNRNPA2B1 knockdown MDA-MB-231 cells
Control: MDA-MB-231 cells
|
GSE70061 | |
Regulation |
|
logFC: 6.38E-01 p-value: 4.72E-02 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | hnRNPA2B1 promotes colon cancer progression via the MAPK pathway. hnRNPA2B1 is an upstream regulator of the Ephrin type-B receptor 2 (ERK/EPHB2)/MAPK pathway and inhibition of MAPK signaling blocked the effects of hnRNPA2B1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colon cancer | ICD-11: 2B90 | ||
Pathway Response | MAPK signaling | hsa04010 | ||
Apoptosis | hsa04210 | |||
Cell Process | Arrest cell cycle at G0/G1 phase | |||
Cell apoptosis | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | Four-week-old male BALB/c nude mice (purchased from Lingchang company) were randomly divided into three groups, each group has five mice. Each of the mice was injected subcutaneously on the right lateral back with 1 × 106 of each lentivirus infected SW480 cells in which hnRNPA2B1 was knocked out or negative control cells. Mice were killed at day 29, and tumors were then isolated, photographed. | |||
Methyltransferase-like 14 (METTL14) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14 | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Treatment: siMETTL14 MDA-MB-231 cells
Control: MDA-MB-231 cells
|
GSE81164 | |
Regulation |
|
logFC: -7.89E-01 p-value: 4.97E-05 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contributes to regeneration. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Muscular dystrophies | ICD-11: 8C70 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | Caco-2 cell line | Homo sapiens |
Treatment: shMETTL3 Caco-2 cells
Control: shNTC Caco-2 cells
|
GSE167075 | |
Regulation |
|
logFC: -6.74E-01 p-value: 5.11E-30 |
More Results | Click to View More RNA-seq Results |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [4] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through p38/Ephrin type-B receptor 2 (ERK/EPHB2) pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contributes to regeneration. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Muscular dystrophies | ICD-11: 8C70 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
Acute myeloid leukaemia [ICD-11: 2A60]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | FTO depended on its m6A RNA demethylase activity to activate PDGFRB/Ephrin type-B receptor 2 (ERK/EPHB2) signaling axis. FTO-mediated m6A demethylation plays an oncogenic role in NPM1-mutated Acute myeloid leukemia(AML). | |||
Responsed Disease | Acute myeloid leukaemia [ICD-11: 2A60] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | OCI-AML-3 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1844 |
OCI-AML-2 | Adult acute myeloid leukemia | Homo sapiens | CVCL_1619 | |
Colon cancer [ICD-11: 2B90]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | hnRNPA2B1 promotes colon cancer progression via the MAPK pathway. hnRNPA2B1 is an upstream regulator of the Ephrin type-B receptor 2 (ERK/EPHB2)/MAPK pathway and inhibition of MAPK signaling blocked the effects of hnRNPA2B1. | |||
Responsed Disease | Colon cancer [ICD-11: 2B90] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling | hsa04010 | ||
Apoptosis | hsa04210 | |||
Cell Process | Arrest cell cycle at G0/G1 phase | |||
Cell apoptosis | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | Four-week-old male BALB/c nude mice (purchased from Lingchang company) were randomly divided into three groups, each group has five mice. Each of the mice was injected subcutaneously on the right lateral back with 1 × 106 of each lentivirus infected SW480 cells in which hnRNPA2B1 was knocked out or negative control cells. Mice were killed at day 29, and tumors were then isolated, photographed. | |||
Colorectal cancer [ICD-11: 2B91]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [4] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through p38/Ephrin type-B receptor 2 (ERK/EPHB2) pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Muscular dystrophies [ICD-11: 8C70]
In total 3 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contributes to regeneration. | |||
Responsed Disease | Muscular dystrophies [ICD-11: 8C70] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contributes to regeneration. | |||
Responsed Disease | Muscular dystrophies [ICD-11: 8C70] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
Experiment 3 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A writers METTL3/METTL14 and the m6A reader YTHDF1 orchestrate MNK2 expression posttranscriptionally and thus control Ephrin type-B receptor 2 (ERK/EPHB2) signaling, which is required for the maintenance of muscle myogenesis and contribute to regeneration. | |||
Responsed Disease | Muscular dystrophies [ICD-11: 8C70] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
C2C12 | Normal | Mus musculus | CVCL_0188 | |
In-vivo Model | For mouse muscle injury and regeneration experiment, tibialis anterior (TA) muscles of 6-week-old male mice were injected with 25 uL of 10 uM cardiotoxin (CTX, Merck Millipore, 217503), 0.9% normal saline (Saline) were used as control. The regenerated muscles were collected at day 1, 3, 5, and 10 post-injection. TA muscles were isolated for Hematoxylin and eosin staining or frozen in liquid nitrogen for RNA and protein extraction. | |||
References